びまん性星状細胞腫
- 同
- びまん性星状細胞腫
WordNet
- spread out; not concentrated in one place; "a large diffuse organization"
- move outward; "The soldiers fanned out" (同)spread, spread out, fan out
- lacking conciseness; "a diffuse historical novel"
- (of light rays) subjected to scattering by reflection from a rough surface or transmission through a translucent material; "diffused light"
- spreading by diffusion (同)diffusive, dispersive, disseminative
PrepTutorEJDIC
- 〈光・熱・液体など〉‘を'散らす,放散する,拡散させる / 〈学問・知識など〉‘を'広める,普及させる / 散る,放散する,拡散する / 広まる,普及する / 広く散った,広がった / 〈文体などが〉締まりのない,散漫な
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
- Curran MP.SourceAdis, a Wolters Kluwer Business, Auckland, New Zealand.
- Paediatric drugs.Paediatr Drugs.2012 Feb 1;14(1):51-60. doi: 10.2165/11207730-000000000-00000.
- Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR). Everolimus (starting dosage 3.0 mg/m2) was associated with a significant reduction in the volume of the largest subependymal giant cell astrocytoma (SEGA) in 28 patients aged ≥3 years with tuberous sclero
- PMID 22136276
- Innate Immunity in multiple sclerosis white matter lesions: expression of natural cytotoxicity triggering receptor 1 (NCR1).
- Durrenberger PF, Ettorre A, Kamel F, Webb LV, Sim M, Nicholas RS, Malik O, Reynolds R, Boyton RJ, Altmann DM.AbstractABSTRACT: BACKGROUND: Pathogenic or regulatory effects of natural killer (NK) cells are implicated in many autoimmune diseases, but evidence in multiple sclerosis (MS) and its murine models remains equivocal. In an effort to illuminate this, we have here analysed expression of the prototypic NK cell marker, NCR1 (natural cytotoxicity triggering receptor; NKp46; CD335), an activating receptor expressed by virtually all NK cells and therefore considered a pan-marker for NK cells. The only definitive ligand of NCR1 is influenza haemagglutinin, though there are believed to be others. In this study, we investigated whether there were differences in NCR1+ cells in the peripheral blood of MS patients and whether NCR1+ cells are present in white matter lesions. Results: We first investigated the expression of NCR1 on peripheral blood mononuclear cells and found no significant difference between healthy controls and MS patients. We then investigated mRNA levels in central nervous system (CNS) tissue from MS patients: NCR1 transcripts were increased more than 5 times in active disease lesions. However when we performed immunohistochemical staining of this tissue, few NCR1+ NK cells were identified. Rather, the major part of NCR1 expression was localised to astrocytes, and was considerably more pronounced in MS patients than controls. In order to further validate de novo expression of NCR1 in astrocytes, we used an in vitro staining of the human astrocytoma U251 cell line grown to model whether cell stress could be associated with expression of NCR1. We found up-regulation of NCR1 expression in U251 cells at both the mRNA and protein levels. Conclusions: The data presented here show very limited expression of NCR1+ NK cells in MS lesions, the majority of NCR1 expression being accounted for by expression on astrocytes. This is compatible with a role of this cell-type and NCR1 ligand/receptor interactions in the innate immune response in the CNS in MS patients. This is the first report of NCR1 expression on astrocytes in MS tissue: it will now be important to unravel the nature of cellular interactions and signalling mediated through innate receptor expression on astrocytes.
- Journal of neuroinflammation.J Neuroinflammation.2012 Jan 2;9(1):1. [Epub ahead of print]
- ABSTRACT: BACKGROUND: Pathogenic or regulatory effects of natural killer (NK) cells are implicated in many autoimmune diseases, but evidence in multiple sclerosis (MS) and its murine models remains equivocal. In an effort to illuminate this, we have here analysed expression of the prototypic NK cel
- PMID 22212381
- IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom.
- Stockhammer F, Misch M, Helms HJ, Lengler U, Prall F, von Deimling A, Hartmann C.SourceDepartment of Neurosurgery, University Medical Center Göttingen, 37075 Göttingen, Germany; Department of Neurosurgery, University Rostock, 18057 Rostock, Germany.
- Seizure : the journal of the British Epilepsy Association.Seizure.2012 Jan 2. [Epub ahead of print]
- INTRODUCTION: Seizures are the most common initial symptom in patients with low-grade glioma and their occurrence strongly depends on the tumor location. The majority of low-grade gliomas reveal mutations in the genes encoding isocitrate-dehydrogenase 1 (IDH1) or 2 (IDH2). These mutations are associ
- PMID 22217666
Japanese Journal
- 脳幹部神経膠腫 (新時代の脳腫瘍学--診断・治療の最前線) -- (脳腫瘍の病理)
- Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis
- Watanabe Yosuke,Yamasaki Fumiyuki,Kajiwara Yoshinori,Saito Taiichi,Nishimoto Takeshi,Bartholomeusz Chandra,Ueno Naoto T,Sugiyama Kazuhiko,Kurisu Kaoru,ワタナベ ヨスケ,ヤマサキ フミユキ,カジワラ ヨシノリ,サイトウ,タイイチ,ニシモト タケシ,ウエノ ナオト,スギヤマ カズヒコ,クリス カオル,渡邊 陽祐,山崎 文之,梶原 佳則,齋藤 太一,西本 武史,上野 直人,杉山 一彦,栗栖 薫
- Journal of Neuro-Oncology 100(3), 449-457, 2010-12
- … We studied the PEA-15 expression pattern of 65 patients [diagnosed according to World Health Organization (WHO) criteria] with diffuse astrocytoma (WHO grade II), anaplastic astrocytoma (grade III), and glioblastoma (grade IV). …
- NAID 120002753666
Related Links
- diffuse astrocytoma, anaplastic astrocytoma, glioblastoma. 神経膠腫（グリオーマ） を代表する星細胞系腫瘍は，脳の主要な構成細胞である星細胞から発生する腫瘍です; 星細胞系腫瘍は，治療の方法と予後との関連で，星細胞腫（せいさいぼうしゅ），退形成 ...
- 星細胞 (astrocyte)より発生し，比較的高い分化度 (well-differentiated)を示す．1997年 のWHO分類では“low-grade diffuse astrocytoma”，2000年版からは“diffuse astrocytoma”という用語が使用され，2007年版でも踏襲されている．組織学的に fibrillary ...
★リンクテーブル★
[★]
- 英
- brain tumor, cerebral tumor
- 同
- 脳新生物 brain neoplasm
- 関
- 頭蓋内腫瘍
概念
分類
-
-
疫学
- 発生率：10万人対10-15人。罹患率：10万人対46人 →
腫瘍別発生頻度
YN.J.188
小児の脳腫瘍
- SCN.173
- 腫瘍：星細胞腫、髄芽腫、頭蓋咽頭腫、胚細胞腫、上衣腫の順に多い。
- 部位：1歳まではテント上、2-7歳まではテント下、8-15歳まではテント上に多い。
- SRA.163
|
|
後発年齢
|
好発部位
|
| 小脳星細胞腫
|
5～10歳
|
小脳半球
|
| 髄芽腫
|
5～10歳(男児に多い)
|
小脳虫部から発生
|
| 頭蓋咽頭腫
|
10～15歳
|
トルコ鞍上部
|
| 上衣腫
|
10～15,30～40歳
|
第四脳室、側脳室
|
| 髄芽腫
|
10～30歳
|
松果体部、トルコ鞍上部
|
| 脳幹部膠腫
|
～15歳
|
橋
|
| 視神経膠腫
|
～15歳
|
視神経視交叉
|
放射線感受性
- SCN.173
転移性脳腫瘍
- 肺癌(約半数)、乳癌、消化器癌、腎癌
- 頻度：肺癌＞乳癌＞胃・腸癌 (SCN.173)
石灰化が見られる脳腫瘍
- 乏突起膠腫：CT上、低吸収領域の中に石灰化がみられる。(SCN.173)
- 上衣腫：CT：(単純CT)等～低吸収、(造影CT)中～強度の増強。小嚢胞や壊死、石灰化を認める
- 髄膜腫：腫瘍の一部石灰化が少なからず見られる
- 頭蓋咽頭腫：小児において石灰沈着が高頻度にみられる。
嚢胞性腫瘍
参考
- http://www.gsic.jp/cancer/cc_19/hc/02.html
- 1-1. がんサポートセンター 脳腫瘍 フローチャート
- http://www.gsic.jp/cancer/cc_19/hc/cc_19_021.html
- http://www.ebm.jp/disease/brain/07noshuyo1/guide.html
- http://ganjoho.ncc.go.jp/public/cancer/data/brain_adult.html
- http://ganjoho.ncc.go.jp/public/cancer/data/brain_child.html
- http://www.geocities.jp/ululu_o_ululu/report-11.html
国試
[★]
- 英
- astrocytoma
- 同
- 星細胞腫、アストロサイトーマ、星状膠細胞腫
- 関
- 星状腫、アストログリオーマ、astroglioma、astrocytic glioma、退形成星状細胞腫、毛様細胞性星細胞腫、上衣下巨細胞星状細胞腫、混合神経膠腫、星状細胞腫、星状芽細胞腫、肥胖性星細胞腫、グレードII星細胞腫、グレードIII星細胞腫、グレードI星細胞腫、線維性星細胞腫、若年性毛細胞性星細胞腫
[show details]
好発部位
- 小児：小脳半球 → 小脳失調
- 成人：大脳半球 → 痙攣
分類
-
-
特徴
- 浸潤性に発育 → 全摘が困難 → 再発しやすい・再発時に悪性化する傾向がある
- 遠隔転移はきわめて稀
- 放射線に対する感受性が低い
- 抗癌薬が効きにくい。
[★]
- 英
- glioma
- 同
- 神経上皮性腫瘍、グリオーマ、神経膠細胞性腫瘍 glial tumor、神経膠細胞腫、膠腫
- 関
- 脳腫瘍
分類
-
悪性神経膠腫の予後規定因子
- 悪性度(悪性度が低いこと = WHO gradeが小さい)
- 年齢(若いこと)
- 腫瘍切除(腫瘍の残存が少ないこと)
- 放射線療法(70Gy以上がよい)
- Performance status(PS)(治療前の神経症状が軽いこと)
- secondary glioblastoma(悪性転化型であること)
- primary glioblastomaは放射線に抵抗性であり、治療しづらい。
参考
- http://ganjoho.jp/public/cancer/data/glioma.html
[★]
- 英
- diffuse astrocytoma
- 関
- 星状細胞腫
[★]
テント上びまん性星状細胞腫
[★]
- 関
- diffusely、diffusion、diffusional、diffusive、disseminated、pervasive、spread、widespread